Fenwick & West represented Royalty Pharma in the transaction. Geron Corporation (Nasdaq: GERN) announced that Royalty Pharma (Nasdaq: PRRX), a buyer of biopharmaceutical royalties and funder...
Geron Corporation’s $375 Million Funding
Royalty Pharma’s $150 Million Royalty Funding Agreement with Ascendis Pharma
Fenwick & West and Goodwin Procter represented Royalty Pharma plc in the transaction, and Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S. Ascendis Pharma A/S...
Royalty Pharma’s Partnership with Teva Pharmaceuticals International GmbH
Gibson, Dunn & Crutcher LLP advised Royalty Pharma in connection with its development funding. Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
Ascendis Pharma’s $150 Million Royalty Funding Agreement with Royalty Pharma
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
Royalty Pharma $500 Million Royalty Agreement with Ferring Pharmaceuticals
Fenwick & West represented Royalty Pharma, and Orrick Herrington & Sutcliffe represented Ferring Pharmaceuticals in the deal. Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals announced...
PureTech Health and Royalty Pharma’s KarXT Royalty Agreement
Jones Day advised Royalty Pharma on the deal. Royalty Pharma have acquired a $500m interest in PureTech’s royalty in Karuna Therapeutics’ KarXT, with $100m cash up...
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
Royalty Pharma’s Interest Acquisition in Amgen’s Olpasiran
Fenwick represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced the...
Royalty Pharma’s $425 Million Funding Agreements with Merck
Fenwick represents Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced IP diligence...
Royalty Pharma’s Acquisition of Royalty Interest in TRELEGY ELLIPTA
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
Royalty Pharma’s Acquisition of Theravance Respiratory Company
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...